To assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of oral administration of AZD8329 - AZ8329

Study identifier:D2350C00010

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Single Centre, Single-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of oral AZD8329 after Administration of Multiple Ascending Doses in Abdominally Obese but otherwise Healthy Male Subjects

Medical condition

overweight, Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD8329, Placebo

Sex

Male

Actual Enrollment

Study type

Interventional

Age

20 Years - 50 Years

Date

Study Start Date: 01 Sept 2010

Primary Completion Date: 01 Dec 2010

Study Completion Date: 01 Dec 2010

Study design

Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2013 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

Location

Research Site

London, United Kingdom

Arms	Assigned Interventions
Placebo Comparator: 1	Drug: Placebo Placebo AZD8329 Oral Solution
Experimental: 2 AZD8329	Drug: AZD8329 AZD8329 Oral Solution 20mg/ml

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1262&filename=CSR-D2350C00010.pdf
Download
CSR-D2350C00010.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Dr. Jan Eriksson

AstraZeneca